Case 1 30/m |
AS 10y |
No |
Etanercept 2.5 m |
PM |
(-) |
MP pulse (1.0 g) |
Improvement |
ANA1:160 Jo-1Anti Jo-1 |
Case 2 20/f |
RA 2y |
Mtx |
Adalimumab 6 m |
PM |
(-) |
MP pulse (1.0 g) |
Improvement |
ANA1:320 Jo-1Anti Jo-1 |
Case 3 44/f |
RA 7y |
Mtx |
Adalimumab 36 m |
DM |
(+) |
MP pulse (1.0 g), CY |
Partial response |
ANA 1:320 Jo-1Anti Jo-1 |
Musial 200344 Musial J, Undas A, Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for RA. Rheumatology (Oxford). 2003;42:1566-8.
52/f |
RA 20y |
Mtx |
Infliximab 30 m |
PM |
(+) |
MP pulse (1.0 g) |
Improvement |
ANA 1:320 AntidsDNA1:20 Jo-1Anti Jo-1 |
Flendrie 200355 Flendrie M, Creemers MCW, Welsing PMC, Den Broeder AA, VanRiel PLCM. Survival during treatment with tumour necrosis factor blocking agents in RA. Ann Rheum Dis. 2003;62:30-3.
|
RA
|
|
|
PM |
|
|
|
|
Flendrie 200566 Flendrie M, Vissers WHPM, Creemers MCW, de Jong J, Van de EMG, Kerkhof KCM, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with RA: a prospective study. Arthritis Res Ther. 2005;7:R666-76.
52/f |
RA
|
|
Lenercept
|
DM |
|
|
Improvement |
|
Urata 200677 Urata Y, Wakai Y, Kowatari K. Polymyositis associated with infliximab treatment for RA. Mod Rheumatol. 2006;16:410-1.
52/f |
RA 33y |
Mtx |
Infliximab 9 m |
PM |
(+) |
30 mg MP |
Improvement |
ANA 1:640 Jo-1Anti Jo-1 |
Hall 200688 Hall HA, Bernard Z. Evolution of dermatomyositis during therapy with a tumor necrosis factor α inhibitor. Arthritis Rheumatol. 2006;55:982-4.
44/f |
RA 1y |
Mtx Hcq |
Etanercept 6 m
|
DM |
(+) |
High dose MP, AZP, MTX |
Improvement |
ANA1:640 Jo-1Anti Jo-1 |
Liozon 200799 Liozon E, Ouattara B, Loustaud-Ratti V, Vidal E. Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma. Scand J Rheumatol. 2007;36:484-6.
42/f |
RA 1.5y |
Mtx Hcq |
Etanercept 9 m |
PM |
(+) |
High dose MP, CY |
Improvement |
ANA 1:2560 Anti-PM-Scl |
Kiltz 20081010 Kiltz U, Fendler C, Braun J. Neuromuscular involvement in rheumatic patients treated with anti-TNF therapy—three examples. J Rheumatol. 2008;35:2074-5.
57/f |
RA 26y |
Mtx Hcq |
Etanercept 30 m
|
PM |
(+) |
High dose MP, CY |
Improvement |
ANA 1:2560 |
Kiltz 20081010 Kiltz U, Fendler C, Braun J. Neuromuscular involvement in rheumatic patients treated with anti-TNF therapy—three examples. J Rheumatol. 2008;35:2074-5.
46/m |
AS 17y |
|
Infliximab 6 m |
PM |
(-) |
|
Improvement |
No |
Ramos-Casals 20081111 Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF targeted therapies. Best Pract Res. 2008;22:847-61.
4 patients |
RA
|
|
Infliximab (2p) Etanercept lenercept |
PM (2p) DM (2p) |
|
|
|
|
Brunasso 20101212 Brunasso AG, Lo Scocco G, Massone C. Dermatomyositis during adalimumab therapy for RA. J Rheumatol. 2010;37:1549-50.
45/f |
RA 13y |
No |
Adalimumab 34 m |
DM |
(-) |
MP |
Improvement |
ANA 1:320 |
Klein 20101313 Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010;146:780-4.
33/f |
RA
|
No |
Etanercept 5 m |
DM |
(+) |
MP |
Improvement |
No |
Klein 20101313 Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010;146:780-4.
40/f |
RA
|
No |
Etanercept 2y |
DM |
(-) |
MP |
Partial response |
ANA |
Klein 20101313 Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010;146:780-4.
29/f |
SNA
|
Mtx |
Adalimumab 3 m |
DM |
(-) |
MP, Mtx, AZP, quinacrine |
Improvement |
ANA 1:640 |
Ishiguro 20101414 Ishiguro T, Takayanagi N, Miyahara Y, Yanagisawa T, Sugita Y. Antisynthetase (anti PL-7 antibody) syndrome presenting as a skin rash and exacerbation of interstitial pneumonia during treatment for RA. Nihon Kokyuki Gakkai Zasshi. 2010;48:240-6.
52/m |
RA 12y |
Mtx, Buc,Tac |
Etanercept 26 m |
DM |
(+) |
MP pulse (1.0 g) |
Improvement |
Anti-PL-7 |
Ishikawa 201033 Ishikawa Y, Yukawa N, Ohmura K, Hosono Y, Imura Y, Kawabata D, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with RA: a case report and review of the literature. Clin Rheumatol. 2010;29:563-6.
58/f |
RA 2y |
Buc,Tac |
Etanercept 2 m |
PM |
(+) |
MP pulse (0.5 g) |
Improvement |
ANA 1:320 Jo-1Anti Jo-1 |
Ishikawa 20111515 Ishikawa Y, Yukawa N, Kawabata D, Ohmura K, Fujii T, Usui T, et al. A case of antisynthetase syndrome in a RA patient with anti-PL-12 antibody following treatment with etanercept. Clin Rheumatol. 2011;30:429-32.
63/f |
RA 6m |
Buc,Tac |
Etanercept 2 m |
PM |
(+) |
PSL 1 mg/kg |
Improvement |
ANA 1:160 Anti-PL-12 |
Riolo, 20121616 Riolo G, Towheed TE. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J Rheumatol. 2012;39:192-4.
36/m |
Crohn 1y |
Mtx |
Adalimumab 2w Infliximab 1 m |
DM |
(-) |
MP, Mtx |
Improvement |
ANA 1:640 Anti-U1 RNP |
Liu 20131717 Liu SW, Velez NF, Lam C, Femia A, Granter SR, Townsend HB, et al. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis. JAMA Dermatol. 2013;149:1204-8.
46/m |
JIA 36y |
Mtx |
Etanercept 10y Adalimumab 2 weeks |
DM |
(-) |
MP, Mtx |
Improvement |
No |